Shares of weight-loss drug developers including Eli Lilly & Co., Novo Nordisk and Structure Therapeutics fell sharply early Wednesday after Roche Holding AG announced early-stage trial data for its experimental obesity pill.
Roche obesity-pill trial results weigh on shares of Eli Lilly, Novo Nordisk
